Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUPRES-250 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (adjunctive therapy),Edema associated with congestive heart failure, cirrhosis, or renal disease (hydrochlorothiazide component)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
250 mg orally twice daily
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hydrochlorothiazide is not metabolized; excreted unchanged by the kidneys. Reserpine undergoes extensive hepatic metabolism via CYP3A4 oxidation.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Hydroflumethiazide: 75-80% bound to plasma proteins. Reserpine: approximately 95% bound (primarily to albumin).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Hydroflumethiazide: 3-8 L/kg (extensive distribution). Reserpine: 9-12 L/kg (highly lipid-soluble, crosses blood-brain barrier).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: hydroflumethiazide ~70% (variability); reserpine ~40% (first-pass metabolism).
70-90% (oral); 100% (IV).
Contraindicated if GFR <30 m L/min. For GFR 30-60 m L/min: use 1 tablet every other day; avoid if GFR <30 m L/min.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or increase dosing interval. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for pediatric use due to reserpine component; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 1 tablet every other day; monitor for electrolyte disturbances, orthostatic hypotension, and central nervous system effects.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA black box warning identified. Reserpine use may be associated with increased risk of breast cancer (historical concern, not confirmed), but no official boxed warning.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Hyperuricemia and gout,Increased blood urea nitrogen (BUN) and creatinine,Photosensitivity with thiazides,Mental depression with reserpine (history of depression, suicidal ideation),Bradycardia, hypotension, and sedation with reserpine,Exacerbation of peptic ulcer disease (reserpine increases gastric acid secretion),Possible withdrawal syndromes (severe hypertension, tachycardia) upon abrupt discontinuation
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide-derived drugs,Anuria or severe renal impairment,Active peptic ulcer disease or ulcerative colitis,History of major depression or electroconvulsive therapy,Concurrent use with MAO inhibitors (MAOIs) or within 14 days of discontinuation,Pheochromocytoma (reserpine may cause paradoxical hypertension),Electroconvulsive therapy (relative contraindication due to risk of prolonged seizure or apnea)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods to enhance antihypertensive effect. Alcohol may increase orthostatic hypotension. Grapefruit juice may alter reserpine metabolism (caution). Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) if also taking MAOIs, but not typically required with reserpine alone. Maintain adequate potassium intake (bananas, oranges) due to hydrochlorothiazide-induced potassium loss.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermia; reserpine crosses placenta and may cause neonatal respiratory depression and nasal congestion.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk; M/P ratio not established; reserpine may cause infant drowsiness, bradycardia, and GI upset; hydrochlorothiazide may decrease milk supply; generally avoid breastfeeding or use with caution.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Increased plasma volume and renal clearance in pregnancy may require dose adjustment for hydrochlorothiazide; reserpine pharmacokinetics not well studied; use lowest effective dose; gradual dose reduction recommended near term to avoid neonatal effects.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
DIUPRES-250 (hydrochlorothiazide 25 mg / reserpine 0.125 mg) is a fixed-dose combination antihypertensive. Reserpine depletes catecholamines, causing orthostatic hypotension and nasal congestion. Hydrochlorothiazide may cause hypokalemia, hyperglycemia, and photosensitivity. Avoid in patients with history of depression (reserpine). Monitor serum potassium, glucose, and uric acid. Onset of full effect may take weeks due to reserpine.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, at the same time each day.,Stand up slowly to avoid dizziness or fainting.,Expect nasal congestion which may improve over time.,Use sunscreen and protective clothing to avoid sunburn.,Do not stop abruptly without consulting your doctor (risk of severe hypertension).,Report any mood changes, breast tenderness, or abdominal pain to your doctor.,Avoid driving or operating machinery until you know how this medicine affects you.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUPRES-250 vs ALDOCLOR-250, answered by our medical review team.
DIUPRES-250 is a Antihypertensive Combination that works by Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUPRES-250 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUPRES-250 is: 1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUPRES-250 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUPRES-250 is classified as Category C. First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermi. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.